What is Genomind?
Genomind operates as a specialized pharmacogenetic testing laboratory, bridging the gap between complex neuropsychiatric disorders and actionable clinical insights. By leveraging the expertise of renowned researchers in psychiatry and neurology, the company provides clinicians with data-driven tools to optimize patient treatment plans. Its core mission centers on uncovering the biological underpinnings of mental health conditions, thereby facilitating a more personalized approach to therapeutic intervention. As a pioneer in the field, Genomind maintains a robust market presence, supported by a history of consistent financial backing that has enabled the scaling of its diagnostic infrastructure and research capabilities.
How much funding has Genomind raised?
Genomind has raised a total of $92.2M across 8 funding rounds:
Series A
$20.9M
Other Financing Round
$5M
Private Equity
$6M
Other Financing Round
$17.9M
Series B
$31.9M
Multiple Rounds
$10.4M
Series A (2014): $21M with participation from Claritas Capital
Other Financing Round (2014): $5M led by Claritas Capital
Private Equity (2015): $6M supported by Claritas Capital
Other Financing Round (2016): $18M featuring Claritas Capital
Series B (2017): $31.9M backed by Silicon Valley Bank
Debt (2020): $1M with participation from PPP
Series C (2020): $4.5M, investors not publicly disclosed
Series D (2020): $4.9M supported by Claritas Capital
Key Investors in Genomind
Claritas Capital
An alternative investments firm based in Nashville, TN, specializing in venture capital and real estate with a focus on healthcare and technology sectors.
Silicon Valley Bank
A prominent financial institution providing commercial and private banking, asset management, and investment services tailored to the innovation economy.
PPP
Public-Private Partnership
What's next for Genomind?
With the recent influx of capital, Genomind is well-positioned to accelerate its research and development initiatives, focusing on the expansion of its diagnostic portfolio and the integration of advanced genomic analytics into standard psychiatric practice. The company's strategic roadmap likely involves scaling its commercial operations to meet the growing demand for precision medicine in mental health. By continuing to leverage its strong investor relationships and deep clinical expertise, Genomind aims to solidify its role as an essential partner for healthcare providers seeking to improve patient outcomes through evidence-based, personalized treatment strategies.
See full Genomind company page
